Consolidation Seen Changing Nature Of Indian Generics Industry
This article was originally published in PharmAsia News
The face that India's pharmaceutical makers have presented to the rest of the industry may be changing. The Indian industry, comprised primarily of makers of generic drugs, has been undergoing a consolidation of late, a move likely to increase market power for the participants, but also reduce competition, thus increasing prices for consumers. The move by Ranbaxy Laboratories to sell to Japan's Daiichi Sankyo has led to speculation about the future of India's generics-making industry. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.